Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy
about
Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitinationmiR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stressSystematic analysis of helical protein interfaces reveals targets for synthetic inhibitorsChemical Variations on the p53 Reactivation ThemeReactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumorsNuclear receptor coregulators: modulators of pathology and therapeutic targetsCharacterizing the dynamics of proteasome complexes by proteomics approachesSmall-molecule inhibitors of myosin proteinsSmall molecule compounds targeting the p53 pathway: are we finally making progress?Inhibition of nutlin-resistant HDM2 mutants by stapled peptidesElucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2In vitro selection of mutant HDM2 resistant to Nutlin inhibitionSmall-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthTransient Protein States in Designing Inhibitors of the MDM2-p53 InteractionAn Ultrahigh Affinity d -Peptide Antagonist Of MDM2Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformationsPP2A: The Achilles Heal in MDS with 5q DeletionMDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.The p53 circuit boardIn vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AMLEvaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assaySimulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamicsIdentification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potentialp53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseasesTime-Dependent Regulation of Apoptosis by AEN and BAX in Response to 2-Aminoanthracene Dietary ConsumptionModes of p53 regulationIn-silico study of small cell lung cancer based on protein structure and function: A new approach to mimic biological system.Stereoselective synthesis of spirocyclic oxindoles via Prins cyclizations.Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.PPIMpred: a web server for high-throughput screening of small molecules targeting protein-protein interaction.USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responsesTargeting tumor suppressor networks for cancer therapeutics.The cis conformation of proline leads to weaker binding of a p53 peptide to MDM2 compared to trans.Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactionsA cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 functionSimultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptideAge-related susceptibility to apoptosis in human retinal pigment epithelial cells is triggered by disruption of p53-Mdm2 association.
P2860
Q24298079-804506E8-0DF4-45F4-A1D7-948455B55DCBQ24630464-195ACACC-934D-40B6-8D44-1AA5AA5D4D67Q24630804-5B260051-F34D-4CAC-A9D8-EB62361FD1DAQ26749008-4339170E-CD17-4D2F-BEFF-D545518A5267Q26783710-611FF333-11EB-44ED-A391-3E0D20CBF896Q26859163-8C0B5526-67C6-4DBA-BCDE-C8FE0CFC949EQ27026945-A9D9A96A-D6F8-4D4B-9336-D76DAB20BD33Q27027635-C0DEECA5-D62E-4E8A-BC23-D22FD80884FEQ27027835-00575811-B454-4EC8-97A1-5B9D662CDE1DQ27301404-CE9C59F3-6B13-469F-950D-56D932EF4B33Q27318807-6878B7B6-720A-459E-B933-92CD87D76D91Q27322456-84BAFEB8-5AE9-460F-9A26-46DABC5D1A44Q27661276-9D2B6C11-ECA8-4AFC-84BA-41589DFB682CQ27680560-677303BE-0C84-4470-A86C-0C1552AB6E8AQ27681154-7855C1E1-6169-4654-BB9B-5C4A8E49ACF6Q27688964-94355558-3595-4605-99AA-B43D530C911AQ27690852-8E81EE30-F6EA-45E0-89D5-A2D8DEEE9E1EQ27853125-06F59A4F-1BA1-4B66-99D0-E4174B1EB773Q28259725-3BBFB376-F5CB-41D4-9FB9-346FCCC29033Q28475341-7A457EAE-E465-4CC8-89E5-3F319B587BE3Q28478434-EF6201F0-815D-4F36-8E7D-5885788F0B3DQ28481334-F9ABC9E1-8CBB-4540-927B-5ABB88A7B980Q28487720-984A8CD5-BF5B-4AC7-BF45-AA6442F4014AQ28611425-C726B426-AACB-4B2B-B568-0FD51822ACE0Q28659936-E3CDBFB3-FE7B-4B4C-896F-46FE96E57614Q29615657-36DCD6AC-BB3E-4012-B0C7-1F9353B30F1CQ30378513-83896173-3A17-4621-8409-E351EEBD87CEQ33498588-57B05DBD-78DA-41E0-BB31-F09874682CF3Q33533630-92BC0A2A-D514-498C-B510-23A2940FD4BFQ33630135-D76F2841-28E5-4C39-9DCE-191480A1B0DEQ33655162-EA19B4DB-97E8-4B59-9F83-4ECA5908304EQ33657519-3D684F31-D059-4019-A9AA-E8EB2822AB32Q33727589-A95C91A5-58D0-444A-B924-A5D3A258D5AAQ33739952-7DC159C4-1085-4194-8296-5AA0CEDE0555Q33759673-B5BEA1C1-13B5-4C69-B894-38194A45417CQ33775959-1F75EF0F-54AB-43B3-A098-BC4E44681926Q33864504-06C9233A-E478-43C1-B2A0-BBDFE07E826FQ33930068-FCD39C29-14A5-48A4-A818-CFDE247B15BAQ33934743-1B0C84C5-11C1-4E43-B90F-7683E704B822Q33961165-25DFEB0E-B547-4185-9A11-87E75976AD71
P2860
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Small-molecule inhibitors of t ...... el approach for cancer therapy
@ast
Small-molecule inhibitors of t ...... el approach for cancer therapy
@en
Small-molecule inhibitors of t ...... el approach for cancer therapy
@nl
type
label
Small-molecule inhibitors of t ...... el approach for cancer therapy
@ast
Small-molecule inhibitors of t ...... el approach for cancer therapy
@en
Small-molecule inhibitors of t ...... el approach for cancer therapy
@nl
prefLabel
Small-molecule inhibitors of t ...... el approach for cancer therapy
@ast
Small-molecule inhibitors of t ...... el approach for cancer therapy
@en
Small-molecule inhibitors of t ...... el approach for cancer therapy
@nl
P2860
P3181
P1476
Small-molecule inhibitors of t ...... el approach for cancer therapy
@en
P2093
Sanjeev Shangary
P2860
P304
P3181
P356
10.1146/ANNUREV.PHARMTOX.48.113006.094723
P407
P50
P577
2009-01-01T00:00:00Z